Deceuninck G - Search Results

1

Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada.

De Wals P, Lefebvre B, Markowski F, Deceuninck G, Defay F, Douville-Fradet M, Landry M. De Wals P, et al. Among authors: deceuninck g. Vaccine. 2014 Mar 14;32(13):1501-6. doi: 10.1016/j.vaccine.2013.11.028. Epub 2014 Jan 31. Vaccine. 2014. PMID: 24486346

2

Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine.

De Wals P, Deceuninck G, Boulianne N, De Serres G. De Wals P, et al. Among authors: deceuninck g. JAMA. 2004 Nov 24;292(20):2491-4. doi: 10.1001/jama.292.20.2491. JAMA. 2004. PMID: 15562128

3

Effectiveness of serogroup C meningococcal polysaccharide vaccine: results from a case-control study in Quebec.

De Wals P, Deceuninck G, De Serres G, Boivin JF, Duval B, Remis R, Massé R. De Wals P, et al. Among authors: deceuninck g. Clin Infect Dis. 2005 Apr 15;40(8):1116-22. doi: 10.1086/428729. Epub 2005 Mar 11. Clin Infect Dis. 2005. PMID: 15791510

4

Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children.

Duval B, Gîlca V, Boulianne N, Deceuninck G, Rochette L, De Serres G. Duval B, et al. Among authors: deceuninck g. Vaccine. 2005 Jul 1;23(31):4082-7. doi: 10.1016/j.vaccine.2004.07.022. Epub 2004 Aug 9. Vaccine. 2005. PMID: 15963363 Clinical Trial.

5

Risk of Guillain-Barré syndrome following serogroup C meningococcal conjugate vaccine in Quebec, Canada.

De Wals P, Deceuninck G, Boucher RM, Ouakki M. De Wals P, et al. Among authors: deceuninck g. Clin Infect Dis. 2008 Apr 15;46(8):e75-7. doi: 10.1086/533469. Clin Infect Dis. 2008. PMID: 18444843

6

Epidemiology of Guillain-Barré syndrome in the province of Quebec.

Deceuninck G, Boucher RM, De Wals P, Ouakki M. Deceuninck G, et al. Can J Neurol Sci. 2008 Sep;35(4):472-5. doi: 10.1017/s0317167100009136. Can J Neurol Sci. 2008. PMID: 18973064

7

Analysis of mortality following a mass immunization campaign with serogroup C meningococcal conjugate vaccine: methodological difficulties and imperfect solutions.

De Wals P, Deceuninck G, Ouakki M, Boulianne N, De Serres G, Danzig L. De Wals P, et al. Among authors: deceuninck g. Vaccine. 2009 May 21;27(24):3223-7. doi: 10.1016/j.vaccine.2009.02.055. Epub 2009 Feb 24. Vaccine. 2009. PMID: 19446195

8

Reduced physician claims for otitis media after implementation of pneumococcal conjugate vaccine program in the province of Quebec, Canada.

Wals PD, Carbon M, Sévin E, Deceuninck G, Ouakki M. Wals PD, et al. Among authors: deceuninck g. Pediatr Infect Dis J. 2009 Sep;28(9):e271-5. doi: 10.1097/INF.0b013e3181bad212. Pediatr Infect Dis J. 2009. PMID: 19710582

9

Antibody and immune memory persistence after vaccination of preadolescents with low doses of recombinant hepatitis B vaccine.

Gilca V, De Serres G, Boulianne N, De Wals P, Murphy D, Trudeau G, Deceuninck G, Massé R, Duval B. Gilca V, et al. Among authors: deceuninck g. Hum Vaccin. 2010 Feb;6(2):212-8. doi: 10.4161/hv.6.2.10299. Epub 2010 Feb 11. Hum Vaccin. 2010. PMID: 19946212

10

Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada.

Deceuninck G, De Wals P, Boulianne N, De Serres G. Deceuninck G, et al. Pediatr Infect Dis J. 2010 Jun;29(6):546-9. doi: 10.1097/INF.0b013e3181cffa2a. Pediatr Infect Dis J. 2010. PMID: 20125062

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters